10.22376/ijpbs.2019.10.1.p1-12 Volume 2 Issue 4 2011 (October - December) The current paper describes lessThan i greaterThan in vitro-in vivo lessThan /i greaterThan correlation (IVIVC) development for extended-release solid oral dosage forms containing BCS Class I, II and III APIs: trimetazidine, indapamide and ciprofloxacin. Dissolution kinetics (in 3 media: 0.1 M or 0.01 M hydrochloric acid, acetate buffer pH 4.3, phosphate buffer pH 6.8) and pharmacokinetic properties of evaluated drugs were studied. Level B IVIVC was established for each of evaluated solid oral dosage forms, correlation coefficients (r) were 0.97, 0.94 and 0.96 for trimetazidine, indapamide and ciprofloxacin drugs, respectively. I. E. Shohin, G. V. Ramenskayaand A. Y. Savchenko In vitro-in vivo correlation (IVIVC), dissolution, trimetazidine, indapamide, ciprofloxacin. 573-580